CADTH Canadian Drug Expert Committee recommendation: Insulin degludec (Tresiba -- Novo Nordisk Canada Inc.) indication : diabetes mellitus, types I and II.
The CADTH Canadian Drug Expert Committee (CDEC) recommends that insulin degludec be reimbursed for the once-daily treatment of adults with diabetes mellitus to improve glycemic control
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2017, October 18, 2017
|
Edition: | Version 1.0 |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that insulin degludec be reimbursed for the once-daily treatment of adults with diabetes mellitus to improve glycemic control |
---|---|
Item Description: | "Final." |
Physical Description: | 1 PDF file (8 pages) |